Skip to main content
. 2019 Jun 3;2019:1805841. doi: 10.1155/2019/1805841

Table 3.

IC50 of everolimus (EVR) formulations against glioblastoma cells (LN 229 and U87) and astrocytes.

Cell line Free-EVR (µM) rHDL-EVR (µM)
LN229 >50 0.27±0.05
U87 2.91±0.3 0.92±0.17
Astrocytes 4.27±0.82 15.1±1.24

Note: a range of concentration of 10 nM to 50 µM of each formulation was used for the cytotoxicity studies.